← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV14행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
AAV2/5-hPDE6B (AAV2/5-hPDE6B)
eyeDNA Therapeutics·Retinitis Pigmentosa
1 trials
Overview
Program
AAV2/5-hPDE6B
Overview
Company
eyeDNA Therapeutics
Overview
Modality
CGT
Overview
Target
Retinitis Pigmentosa
Overview
Indication
Retinitis Pigmentosa
Overview
Phase
PHASE_2
Overview
Status
DISCONTINUED
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation.. Glioblastoma (GBM) is a highly aggressive type of brain cancer associated with poor prognosis due to limited effective treatment options. Adeno-associated viral (AAV) vector-based gene therapy strategies have demonstrated promise in preclinical models of GBM, but inter- and intratumor cellular heterogene…
Clinical
Safety signal
AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation.. Glioblastoma (GBM) is a highly aggressive type of brain cancer associated with poor prognosis due to limited effective treatment options. Adeno-associated viral (AAV) vector-based gene therapy strategies have demonstrated promise in preclinical models of GBM, but inter- and intratumor cellular heterogene…
Clinical
Program phase
PHASE_2